沙美特罗/氟替卡松与布地奈德/福莫特罗对中重度稳定期慢性阻塞性肺病肺功能和生活质量的比较研究

目的比较长期联合吸入布地奈德/福莫特罗和沙美特罗/氟替卡松对中重度稳定期慢性阻塞性肺病（COPD）患者的肺功能、生活质量的影响。方法 180例中重度稳定期COPD患者随机分为规律吸入布地奈德福莫特罗（160μg/4.5μg）组60例,规律吸入沙美特罗/氟替卡松组（50μg/250μg）60例,按需吸入特布他林组60例（对照组）。测定三组试验前及试验后6个月圣.乔治（St.George）呼吸疾病问卷（SGRQ）的评分,6 min行走距离（6-MWD）肺功能。结果布地奈德/福莫特罗组与沙美特罗/氟替卡松组治疗后较对照组生活质量,6-MWD增加,肺功能改善,其差异有统计学意义（P〈0.05）;布地奈德/福莫特罗组与沙美特罗/氟替卡松组间比较,差异无统计学意义（P〉0.05）。结论与沙美特罗/氟替卡松一样,规律吸入布地奈德/福莫特罗能改善中重度稳定期COPD病人的临床症状、运动耐力和肺功能。

Comparative study on effect of inhaling salmeterol/fluticasone and budesonide/formoterol to the lung function and health-related quality of life of patients with moderate or severe stable COPD

Objective To compare the influence of combination therapy of chronically inhaling budesonide/formoterol and salmeterol/fluticasone on lung function,health-related quality of life of patients with moderate or severe stable COPD. Methods 180 patients with moderate or severe COPD in stabilization period were randomly divided into control group（terbutaline treatment group） 60 cases,budesonide/formoterol treatment group 60 cases,salmeterol/fluticasone treatment group 60 cases.The St.George＇s hospital respiratory questioners（SGRQ）,lung function and walking distance of 6 minutes（6-MWD） were measured before treatment and 6 months after treatment. Results Compared to the control group,the score of health-related quality of life,the lung function,6-MWD in treatment group all had obviously improved after 6 months treatment,the difference had statistically significance（P0.05）.The comparison of salmeterol/fluticasone treatment group and budesonide/formoterol treatment group had no statistically significance（P0.05）. Conclusion The effect of budesonide/formoterol therapy and salmeterol/fluticasone therapy on outcome in moderate or severe stable COPD is similar.